Comparison of remicade to curcumin for the treatment of Crohn’s disease: A systematic review
| Autor: | Ivy Hossain, Kara Nicol, Allaire Schneider, Julia VanderMolen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Complementary and Manual Therapy
Oncology medicine.medical_specialty Curcumin Colorectal cancer Anti-Inflammatory Agents Complementary therapy Disease CINAHL Malignancy 03 medical and health sciences chemistry.chemical_compound Curcuma 0302 clinical medicine Crohn Disease Internal medicine medicine Humans Advanced and Specialized Nursing Crohn's disease Plant Extracts Tumor Necrosis Factor-alpha business.industry Cancer medicine.disease Infliximab Complementary and alternative medicine chemistry 030220 oncology & carcinogenesis Immunology 030211 gastroenterology & hepatology Colorectal Neoplasms business Interleukin-1 Phytotherapy |
| Zdroj: | Complementary Therapies in Medicine. 33:32-38 |
| ISSN: | 0965-2299 |
| Popis: | Objective The aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary therapy in treating Crohn’s Disease (CD) in conjunction with Remicade. Design Systematic searches were performed by three researchers using electronic databases (ProQuest Medical Library, CINAHL Complete, and PUBMED) to locate and identify articles to meet a predetermined set of inclusion criteria. Specifically full text, peer-reviewed articles published after 2007 were included if they studied human participants 18 years or older. Results Tumor necrosis factor-alpha (TNF-a) and Interleukin-1 (IL-1) levels increase in CD patients. Remicade reduces TNF-a in adults with CD. The issues are eventual loss of response (LOR) once IL-1 increases, and severe risks such as malignancy. CD patients using Curcumin saw a 55 point mean reduction in the Crohn’s Disease Activity Index, reducing IL-1 and Crp. Plus it reduced TNF-a and PPMTase which improved colorectal cancer outcomes. Conclusions LOR of Remicade occurs when IL-1 increases, and it can cause malignancy. Research shows Curcumin reduces IL-1 and improves cancer outcomes. Future research, using both Remicade and Curcumin, would have to be done, but preliminary data would suggest using both would reduce LOR. Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect